The trial involved their lead asset, vidofludimus calcium, an orally available nuclear receptor-related 1 activator focused on patients with relapsing-remitting multiple sclerosis.
Conducted by EMD Serono (EMD), the phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study.
It was designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS.
Immunic, Inc. (IMUX) achieved both primary and key secondary endpoints with high statistical significance. The trial also demonstrated a favorable safety and tolerability profile similar to placebo.
This new data from the OLE period is very encouraging and continues to corroborate the prior strong results observed in the phase 2 EMPhASIS trial in RRMS, stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, Inc.
